Lung-care AI company secures $1M from provider-system partner

The venture arm of 32-hospital UnityPoint Health is partnering with VIDA Diagnostics, investing $1 million to fine-tune and broaden the use of VIDA’s AI software for flagging signs of trouble in lung images.

VIDA’s primary product, called LungPrint, automatically analyzes chest CT scans for pulmonary conditions such as emphysema and interstitial lung disease.

The investment allows Iowa-based VIDA to simultaneously tap funds from the Iowa Economic Development Authority, according to a July 25 announcement.

“The State of Iowa is proud of VIDA’s worldwide impact on patients with, or at risk of, lung disease,” said Debi Durham, director of the Iowa Economic Development Authority and Iowa Finance Authority, in prepared remarks. “VIDA and today’s news are great examples of what can happen when public and private partners come together to foster an entrepreneur ecosystem that supports the success of start-ups in our state.”

For UnityPoint, which serves patients throughout Iowa, western Illinois and southern Wisconsin, the investment in VIDA is part of a $100 million program launched in May to support young companies working in digital health, medical devices and other areas.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.